Bevacizumab

About

Therapy type: Targeted therapy

Therapy strategy: VEGF inhibition

Mappings

NCI Thesaurus: Bevacizumab (ncit:C2039)

RxNorm: bevacizumab (rxcui:253337, omop:4247981)

SNOMED: Bevacizumab (sctid:409406007, omop:1397141)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
EMA (1) FDA (1) HSE (1)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	HRD	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	HRD	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
EMA (1) FDA (1)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	HRD	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
FDA (1)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
FDA (1)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
EMA (1) FDA (1) HSE (1)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
FDA (1)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
EMA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Bevacizumab, Erlotinib
EMA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Bevacizumab, Erlotinib
EMA (1)	EGFR somatic variants	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
EMA (1)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
HSE (2)	HER2-negative	Invasive Breast Carcinoma	Bevacizumab, Paclitaxel
HSE (1)	EGFR activating variants	Non-Small Cell Lung Cancer	Bevacizumab, Erlotinib
FDA (1)	PD-L1 (CPS) >= 1	Ovarian Epithelial Tumor	Bevacizumab, Paclitaxel, Pembrolizumab
FDA (1)	PD-L1 (CPS) >= 1	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Paclitaxel, Pembrolizumab
FDA (1)	PD-L1 (CPS) >= 1	Peritoneal Serous Carcinoma	Bevacizumab, Paclitaxel, Pembrolizumab